Clopidogrel Resistance

Categories: Blood diseases, Metabolic diseases

Aliases & Classifications for Clopidogrel Resistance

MalaCards integrated aliases for Clopidogrel Resistance:

Name: Clopidogrel Resistance 25
Cyp2c19-Related Poor Drug Metabolism 25
Poor Metabolism of Clopidogrel 25
Resistance to Clopidogrel 25


Summaries for Clopidogrel Resistance

Genetics Home Reference : 25 Clopidogrel resistance is a condition in which the drug clopidogrel is less effective than normal in people who are treated with it. Clopidogrel (also known as Plavix) is an antiplatelet drug, which means that it prevents blood cells called platelets from sticking together (aggregating) and forming blood clots. This drug is typically given to prevent blood clot formation in individuals with a history of stroke; heart attack; a blood clot in the deep veins of the arms or legs (deep vein thrombosis); or plaque buildup (atherosclerosis) in the blood vessels leading from the heart, which are opened by placement of a small thin tube (stent). People with clopidogrel resistance who receive clopidogrel are at risk of serious, sometimes fatal, complications. These individuals may have another heart attack or stroke caused by abnormal blood clot formation; those with stents can develop blood clots (thromboses) within the stents, impeding blood flow. People with clopidogrel resistance can be divided into two categories: intermediate metabolizers and poor metabolizers. Intermediate metabolizers are able to process some clopidogrel, so they receive partial benefit from the treatment but are not protected from developing a harmful blood clot. Poor metabolizers process little or no clopidogrel, so they receive very limited benefit from the treatment and are at risk of forming a harmful blood clot. Clopidogrel resistance does not appear to cause any health problems other than those associated with clopidogrel drug treatment.

MalaCards based summary : Clopidogrel Resistance, also known as cyp2c19-related poor drug metabolism, is related to drug metabolism, poor, cyp2c19-related and aspirin resistance. An important gene associated with Clopidogrel Resistance is CYP2C19 (Cytochrome P450 Family 2 Subfamily C Member 19), and among its related pathways/superpathways are Metabolism and Cytochrome P450 - arranged by substrate type. The drugs Tirofiban and Heparin have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and kidney, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Clopidogrel Resistance

Diseases related to Clopidogrel Resistance via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 91)
# Related Disease Score Top Affiliating Genes
1 drug metabolism, poor, cyp2c19-related 31.2 P2RY12 CYP2C19
2 aspirin resistance 30.4 PTGS2 P2RY1 ITGB3
3 thrombosis 30.2 VASP SELP P2RY12 P2RY1 ITGB3
4 cerebrovascular disease 29.9 SELP PON1 ITGB3 CYP2C19
5 coronary artery anomaly 29.7 SELP PON1 KDR HMGCR
6 coronary heart disease 1 29.6 SELP PON1 HMGCR
7 coronary thrombosis 29.5 SELP PTGS2 P2RY12 ITGB3
8 stroke, ischemic 28.2 SELP PPIG PON1 P2RY12 HMGCR
9 cardiovascular system disease 28.2 SELP PTGS2 PON1 P2RY12 HMGCR CYP2J2
10 vascular disease 28.1 SELP PTGS2 PON1 ITGB3 HMGCR CYP2C9
11 heart disease 27.8 SELP PPIG PON1 KDR HMGCR CYP2C9
12 myocardial infarction 26.5 SELP PTGS2 PPIG PON1 P2RY12 KDR
13 ischemia 10.6
14 tacrolimus dose selection 10.4 CYP3A5 CYP3A4
15 hyperlipoproteinemia, type iii 10.4
16 arteries, anomalies of 10.4
17 engraftment syndrome 10.4 CYP3A5 ABCB1
18 mixed epithelial stromal tumour 10.3 CYP3A4 CYP1A2
19 phenytoin toxicity 10.2 CYP2C9 CYP2C19 ABCB1
20 esophageal candidiasis 10.2 CYP3A4 CYP2C9 CYP2C19
21 angiodysplasia of intestine 10.2 CYP3A4 CYP2C9 CYP1A2
22 von willebrand's disease 10.2 SELP P2RY12 ITGB3
23 gingival overgrowth 10.1 CYP2C9 CYP2C19 ABCB1
24 hepatocellular adenoma 10.1 CYP3A4 CYP1A2 CYP1A1
25 germ cell cancer 10.1 CYP3A4 CYP1A2 ABCB1
26 intrahepatic cholestasis of pregnancy 10.1 CYP3A4 CYP1A1 ABCB1
27 pulmonary artery disease 10.1 SELP CYP3A4 CYP2C9
28 active peptic ulcer disease 10.1 PTGS2 P2RY12 CYP2C19
29 acute myocardial infarction 10.1
30 bone squamous cell carcinoma 10.1 KDR CYP2C19
31 peptic esophagitis 10.1 PTGS2 CYP2C19
32 functional gastric disease 10.0 PTGS2 CYP3A4 CYP2C19
33 acetaminophen metabolism 10.0 CYP3A4 CYP2C19 CYP1A2 CYP1A1
34 cerebral aneurysms 10.0
35 headache 10.0 PTGS2 CYP1A2 ABCB1
36 body mass index quantitative trait locus 11 10.0
37 body mass index quantitative trait locus 9 10.0
38 body mass index quantitative trait locus 8 10.0
39 body mass index quantitative trait locus 4 10.0
40 body mass index quantitative trait locus 10 10.0
41 body mass index quantitative trait locus 7 10.0
42 body mass index quantitative trait locus 12 10.0
43 body mass index quantitative trait locus 14 10.0
44 body mass index quantitative trait locus 18 10.0
45 body mass index quantitative trait locus 19 10.0
46 body mass index quantitative trait locus 20 10.0
47 angina pectoris 10.0
48 transient cerebral ischemia 10.0
49 lipid metabolism disorder 10.0
50 coronary stenosis 10.0

Graphical network of the top 20 diseases related to Clopidogrel Resistance:

Diseases related to Clopidogrel Resistance

Symptoms & Phenotypes for Clopidogrel Resistance

MGI Mouse Phenotypes related to Clopidogrel Resistance:

# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.81 ABCB1 CYP1A1 CYP1A2 ITGB3 KDR PON1
2 homeostasis/metabolism MP:0005376 9.73 ABCB1 CYP1A1 CYP1A2 HMGCR ITGB3 KDR
3 liver/biliary system MP:0005370 9.23 ABCB1 CYP1A1 CYP1A2 HMGCR ITGB3 KDR

Drugs & Therapeutics for Clopidogrel Resistance

Drugs for Clopidogrel Resistance (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 87)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Tirofiban Approved Phase 4 144494-65-5 60947
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
Atorvastatin Approved Phase 4 134523-00-5 60823
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
Triflusal Approved, Investigational Phase 4 322-79-2
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
Histamine Approved, Investigational Phase 4 51-45-6 774
Sodium citrate Approved, Investigational Phase 4 68-04-2
Pantoprazole Approved Phase 4 102625-70-7 4679
Phenprocoumon Approved, Investigational Phase 4 435-97-2 9908 54680692
Rivaroxaban Approved Phase 4 366789-02-8
Ticagrelor Approved Phase 4 274693-27-5 9871419
Eptifibatide Approved, Investigational Phase 4 188627-80-7 123610
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
Dabigatran Investigational Phase 4 211914-51-1
19 interferons Phase 4
20 Anti-Infective Agents Phase 4
21 Anti-Bacterial Agents Phase 4
22 Antibiotics, Antitubercular Phase 4
23 Immunologic Factors Phase 4
24 Protective Agents Phase 4
25 Antiviral Agents Phase 4
26 Adjuvants, Immunologic Phase 4
27 polysaccharide-K Phase 4
28 calcium heparin Phase 4
29 Radiation-Protective Agents Phase 4
30 Interferon Inducers Phase 4
31 Hypolipidemic Agents Phase 4
32 Rosuvastatin Calcium Phase 4 147098-20-2
33 Anticholesteremic Agents Phase 4
34 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
35 Lipid Regulating Agents Phase 4
36 Calcium, Dietary Phase 4
37 Antimetabolites Phase 4
38 Anti-Asthmatic Agents Phase 4
39 Neuroprotective Agents Phase 4
40 Respiratory System Agents Phase 4
41 Bronchodilator Agents Phase 4
42 Phosphodiesterase Inhibitors Phase 4
43 Autonomic Agents Phase 4
44 Phosphodiesterase 3 Inhibitors Phase 4
45 Vasodilator Agents Phase 4
46 Salicylates Phase 4
47 Proton Pump Inhibitors Phase 4
48 Gastrointestinal Agents Phase 4
49 Anti-Ulcer Agents Phase 4
50 Antacids Phase 4

Interventional clinical trials:

(show top 50) (show all 59)
# Name Status NCT ID Phase Drugs
1 The Dynamic Effect of Non-cytochrome P450 Isoenzyme 3A4(CYP3A4)-Metabolized and Cytochrome P450 Isoenzyme 3A4(CYP3A4)-Metabolized Statins on Clopidogrel Resistance in Patients With Cerebral Infarction Unknown status NCT02411903 Phase 4 atorvastatin and clopidogrel;rosuvastatin and clopidogrel
2 Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel Completed NCT00398463 Phase 4 Tirofiban;Placebo
3 Effects of Intensive Antiplatelet Therapy for Patients With Clopidogrel Resistance After Coronary Stent Implantation Completed NCT01094457 Phase 4 aspirin, clopidogrel;aspirin, clopidogrel, cilostazol
4 Comparison of Triflusal and Clopidogrel Effect in Secondary Prevention of Stroke Based on the Cytochrome P450 2C19 Genotyping Completed NCT01174693 Phase 4 Triflusal;Clopidogrel
5 Effect of Tailored Use of Tirofiban in Patients With Non-ST-elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Completed NCT03114995 Phase 4 Tirofiban
6 Genotype Guided Versus Conventional Approach in Selection of Oral P2Y12 Receptor Blocker in Chinese Patients Suffering From Acute Coronary Syndrome Completed NCT01994941 Phase 4 Clopidogrel;Ticagrelor
7 Prevalence of Resistance to Aspirin and/or Clopidogrel Among Patients With PAD. Prognostic Significance of Resistance to Aspirin Completed NCT00262561 Phase 4 Aspirin
8 Study of Policosanol to Improve High on Clopidogrel Platelet Reactivity After Percutaneous Coronary Stent Implantation(Spirit) Completed NCT01371058 Phase 4 high maintenance clopidogrel;routine dual antiplatelet;policosanol plus dual antiplatelet
9 Evaluation of the Influence of Statins and Proton Pump Inhibitors on Clopidogrel Antiplatelet Effects Completed NCT00930670 Phase 4 Rosuvastatin-omeprazole;Rosuvastatin-pantoprazole;Rosuvastatin-esomeprazole;Rosuvastatin-ranitidine;Atorvastatin-omeprazole;Atorvastatin-pantoprazole;Atorvastatin-esomeprazole;Atorvastatin-ranitidine
10 Phase IV Study of Aspirin and Clopidogrel Therapy Tailored by Functional Thrombocyte Examination (PFA-100, LTA and VerifyNOW) in Acute Myocardial Infarction Completed NCT01381185 Phase 4 Aspirin 200mg qd, Clopidogrel 2x75mg qd
11 A Prospective, Randomized, Controlled, Analyst-blinded, Parallel Group Study to Investigate the Effect of Antithrombotic Triple Therapy With Ticagrelor and Acetylsalicylic Acid in Combination With Dabigatran or Rivaroxaban or Phenprocoumon on Markers of Coagulation Activation in Venous and Shed Blood in Healthy Male Subjects Completed NCT01812200 Phase 4 Dabigatran, Ticagrelor, ASA;Rivaroxaban, Ticagrelor, ASA;Phenprocoumon, Ticagrelor, ASA
12 CYP2C19 Genotype-GUided Dual Antiplatelet theRapy in pAtieNts Treated With New Generation Drug Eluting stEnts (the GUARANTEE Study) Recruiting NCT03783351 Phase 4
13 Research Evaluation to Study Individuals Who Show Thromboxane Or P2Y12 Receptor Resistance Terminated NCT00289601 Phase 4 eptifibatide
14 Clinical Management of Antiplatelet Drug Resistance in Patients With Drug Eluting Coronary Stents Withdrawn NCT00589862 Phase 4 Plavix (Clopidogrel)
15 The Effect of Ticagrelor on Acute Coronary Syndrome Patients With Clopidogrel Resistance Undergoing Percutaneous Coronary Intervention Unknown status NCT01812330 Phase 3 Clopidogrel;Ticagrelor
16 Ticlopidine+Ginkgo Biloba Versus Clopidogrel in Clopidogrel Resistant Patients Undergoing Cartoid Artery Stent Placement Unknown status NCT02133989 Phase 3 Ticlopidine + Ginko biloba;Clopidogrel
17 Optimization of Antiplatelet Therapy With Clopidogrel on the Basis of the Extent of Platelet Inhibition in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy Undergoing PCI With Stent Implantation Unknown status NCT00774475 Phase 3 comparison of different dosage of clopidogrel;doubled therapy
18 ThrombElastoGraphic Haemostatic Status and Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery(TEG-CABG Trial):Does Intensified Postoperative Antiplatelet Therapy in Preoperatively Identified Hypercoagulable Patients Improve Outcome After CABG Surgery Unknown status NCT01046942 Phase 3 Clopidogrel+acetylsalicylic acid;acetylsalicylic acid
19 The EFFect of hIgh Dose ClopIdogrel treatmENT in Patients With Clopidogrel Resistance Completed NCT01032668 Phase 3 Clopidogrel
20 Phase 3 Study of Prasugrel vs High Dose (150 mg) Clopidogrel in Clopidogrel Resistant Patients Post Coronary Angioplasty. Completed NCT01109784 Phase 3 prasugrel;clopidogrel
21 ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation (The RAPID GENE Study) Completed NCT01184300 Phase 2, Phase 3
22 Phase 3 Study Comparing the Efficacy and Safety of Prasugrel and Clopidogrel in Acute Coronary Syndrome Patients With CYP2C19 Polymorphism Who Undergo Percutaneous Coronary Intervention. Completed NCT01641510 Phase 3 Prasugrel;Clopidogrel
23 Efficacy and Safety of Different Ticagrelor Regimens Versus Clopidogrel in Patients With Coronary Artery Disease: a Retrospective Multicenter Study (SUPERIOR) Completed NCT03381742 Phase 2, Phase 3 Ticagrelor;ticagrelor;ticagrelor;clopidogrel
24 Prasugrel in Comparison to High Clopidogrel Dose for Inhibition of Platelet Reactivity as Assessed With a Point-of-Care Platelet Function Assay in Patients Undergoing Chronic Hemodialysis Presenting Resistance to the Usual Clopidogrel Dose Completed NCT01155765 Phase 3 Prasugrel;Clopidogrel
25 Prasugrel Versus High Dose Clopidogrel in Patients With Stable Coronary Artery Disease and High Platelet Reactivity While on Chronic Clopidogrel Treatment Completed NCT01304472 Phase 3 Prasugrel;Clopidogrel
26 Reassessment of Anti-Platelet Therapy Using InDividualized Strategies - Modifying Acute CoroNary Syndrome Algorithms Based on Genetic and Demographic Evaluation: The RAPID-MANAGE Study Completed NCT02044146 Phase 2, Phase 3 Ticagrelor, Prasugrel, Clopidogrel
27 Comparison of Prasugrel and Clopidogrel Reloading on High Platelet Reactivity in Clopidogrel-loaded Patients Undergoing Percutaneous Coronary Intervention Completed NCT01609647 Phase 3 Prasugrel;Clopidogrel
28 ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy in Patients With ST-segment Elevation Myocardial Infarction Completed NCT01452139 Phase 2, Phase 3 Prasugrel
29 Clopidogrel Reloading in Clopidogrel Resistant Patients With ACS Completed NCT00444132 Phase 3 clopidogrel
30 Half-dose Ticagrelor Overcomes High-dose Clopidogrel in Acute Coronary Syndrome Patients With High On-Clopidogrel Platelet Reactivity Recruiting NCT03062462 Phase 2, Phase 3 Clopidogrel;ticagrelor
31 Clopidogrel Pharmacogenomics Project Completed NCT01097343 Phase 2 clopidogrel 75 mg;Clopidogrel 150 mg
32 Effect of Primidone on Platelet Responsiveness in Patients Determined to be Clopidogrel Resistant Withdrawn NCT02008123 Phase 2 Primidone
33 Impact of Omeprazole and Fluvoxamine on Platelet Response to Clopidogrel. a Randomized, Double-blind Placebo Controlled, Crossover Trial Completed NCT01269333 Phase 1 omeprazole;fluvoxamine;placebo
34 The Effect of Ticagrelor and Apixaban With or Without Acetylsalicylic Acid on Markers of Coagulation Activation at the Site of Thrombus Formation in Vivo in Healthy Male Subjects and in an ex Vivo Perfusion Chamber Model at High and Low Shear Rate Completed NCT02080858 Phase 1 Ticagrelor + Apixaban + ASA;Ticagrelor + Apixaban
35 Impact of Citalopharm and Fluvoxamine on Platelet Response to Clopidogrel, a Randomized, Double-blind, Crossover Trial Completed NCT01396720 Phase 1 fluvoxamine;citalopharm
36 Phase 1 Study to Assess the Safety of 500mg of Aspirin Added to IV TPA at Standard Doses to Prevent Re-occlusion of Cerebral Vessels After Successful Reperfusion. Withdrawn NCT00417898 Phase 1 Aspirin
37 The Optimal Regimen of Medical Treatment in Endovascular Therapy in Ischemic Cerebrovascular Disease Based on Clopidogrel Resistance Unknown status NCT01925872
38 Effects of Ramadan Fasting on Clopidogrel Resistance in Patients at High Cardiovascular Risk. An Observational Study Unknown status NCT02624583
39 Prospective Pilot Study- Does Mean Platelet Volume Change With Clopidogrel in Patients With Stable Angina Undergoing Percutaneous Coronary Intervention? Unknown status NCT02550301
40 Thromboelastography As A Tool for Possible Clopidogrel Resistance in The Patients Treated With Primary PCI for STEMI Unknown status NCT00517478
41 Clopidogrel Resistance and Platelet Reactivity in Hispanic Females Undergoing Percutaneous Coronary Intervention Unknown status NCT01796873
42 The Role of Multiple Electrode Aggregometry in Detection of Clopidogrel Resistance in Diabetic Patients With Coronary Artery Disease and Prediction of Clinical Outcomes. A Comparative-method, Non Interventional, Single Center Study. Completed NCT01991093
43 Assessment of Aspirin and Clopidogrel Resistance in Ischemic Heart Disease Using Multiplate Function Analyser and it's Correlation With Major Adverse Cardiac Events Completed NCT00742430
44 The Comparison of Effects Between Increased Dose of Clopidogrel and Addition of Cilostazol in Clopidogrel Non-Responders After Drug-Eluting Stent Implantation Completed NCT00620646 aspirin, clopidogrel;aspirin, clopidogrel, cilostazol
45 Prospective Multi-center Registry of Genotyping Related Clopidogrel in Percutaneous Coronary Intervention Patients Completed NCT02707445 Clopidogrel
46 Prevalence of clOpidogrel "resIstaNce" in a Selected Population of Patients Undergoing Elective Percutaneous Coronary Intervention at a Tertiary Cardiovascular Center in Trinidad: The POINT Pilot Study Completed NCT03667066 Clopidogrel
47 Prevalence of Clopidogrel (Plavix) Resistance in Hemodialysis Patients Completed NCT01865890
48 Aspirin- and Clopidogrel-Resistance: Non-compliance and Other Contributing Factors Completed NCT01039480
49 PREDICT: Scripps Pilot Study on the Effect of High Clopidogrel Maintenance Dosing and Its Relationship to Cytochrome P450 2C19 Polymorphism Status Completed NCT01118793 Clopidogrel
50 The Effect of Aspirin and Thienopyridine Non-responsiveness on Outcomes in Peripheral Arterial Disease Completed NCT03174990

Search NIH Clinical Center for Clopidogrel Resistance

Genetic Tests for Clopidogrel Resistance

Anatomical Context for Clopidogrel Resistance

MalaCards organs/tissues related to Clopidogrel Resistance:

Heart, Testes, Kidney, Brain, Whole Blood, Endothelial, Bone

Publications for Clopidogrel Resistance

Articles related to Clopidogrel Resistance:

(show top 50) (show all 446)
# Title Authors PMID Year
The impact of cytochrome 450 and Paraoxonase polymorphisms on clopidogrel resistance and major adverse cardiac events in coronary heart disease patients after percutaneous coronary intervention. 61
31900240 2020
Coding SNPs in hsa-miR-1343-3p and hsa-miR-6783-3p target sites of CYP2C19 modulates clopidogrel response in individuals with cardiovascular diseases. 61
32001263 2020
Comparison of two preventive dual antiplatelet regimens for unruptured intracranial aneurysm embolization with flow diverter/disrupter: A matched-cohort study comparing clopidogrel with ticagrelor. 61
30731144 2019
The effect of Xuefu Zhuyu decoction on clopidogrel resistance and its association with the P2Y12 Gene polymorphisms and promoter DNA methylation. 61
31969287 2019
Preoperative Light Transmission Aggregometry Values Predict for Thromboembolic Complications After Stent-Assisted Coil Embolization. 61
31704360 2019
Cytochrome 2C19 and paraoxonase-1 polymorphisms and clopidogrel resistance in ischemic heart disease patients. 61
31591927 2019
Association of GCK gene DNA methylation with the risk of clopidogrel resistance in acute coronary syndrome patients. 61
31605429 2019
CYP2C19 loss-of-function alleles: A common but overlooked problem associated with clopidogrel resistance. 61
31385867 2019
Association of CYP2C19 Polymorphism with Clopidogrel Resistance in Patients with Acute Coronary Syndrome in China. 61
31543510 2019
Ticagrelor Use in Indian Patients Undergoing Neuroendovascular Procedures: A Single Center Experience. 61
31387163 2019
Effects of the rs2244613 polymorphism of the CES1 gene on the antiplatelet effect of the receptor P2Y12 blocker clopidogrel. 61
31560647 2019
Genotyping and phenotyping CYP3A4\CYP3A5: no association with antiplatelet effect of clopidogrel. 61
31102151 2019
Neuro-Interventional Use of Oral Antiplatelets: A Survey of Neuro-Endovascular Centers in the United States and Review of the Literature. 61
31327286 2019
Enhanced responsiveness of platelets to vicagrel in IL-10-deficient mice through STAT3-dependent up-regulation of the hydrolase arylacetamide deacetylase in the intestine. 61
30825385 2019
International survey of patients undergoing percutaneous coronary intervention and their attitudes toward pharmacogenetic testing. 61
30724853 2019
Influences of an NR1I2 polymorphism on heterogeneous antiplatelet reactivity responses to clopidogrel and clinical outcomes in acute ischemic stroke patients. 61
30487649 2019
[Status quo and countermeasure of clopidogrel resistance predicted by gene testing]. 61
31055828 2019
Association of PON1 gene promoter DNA methylation with the risk of Clopidogrel resistance in patients with coronary artery disease. 61
30891852 2019
Platelet Surface CD62p and Serum Vitamin D Levels are Associated with Clopidogrel Resistance in Chinese Patients with Ischemic Stroke. 61
30795966 2019
Integrative Medicine on Optimizing Clopidogrel and Aspirin Therapy. 61
29335863 2019
Aspirin and Clopidogrel Resistance in Indian Patients with Ischemic Stroke and its Associations with Gene Polymorphisms: A Pilot Study. 61
31007424 2019
Evaluation of platelet reactivity during combined antiplatelet therapy in patients with stable coronary artery disease in relation to diabetes type 2 and the GPIIB/IIIA receptor gene polymorphism. 61
31356179 2019
Low-dose Prasugrel in Patients with Resistance to Clopidogrel for the Treatment of Cerebral Aneurysms: Follow-up of over 6 Months. 61
30827067 2019
Long Term Cardiovascular Outcome Based on Aspirin and Clopidogrel Responsiveness Status in Young ST-Elevated Myocardial Infarction Patients. 61
30570067 2019
Long non-coding RNA metallothionein 1 pseudogene 3 promotes p2y12 expression by sponging miR-126 to activate platelet in diabetic animal model. 61
29617185 2019
Monitoring of Antiplatelet Therapy in Children on Ventricular Assist Device Support: Comparison of Multiplate and Thromboelastography Platelet Mapping. 61
29489462 2019
Prevalence of clOpidogrel 'resIstaNce' in a selected population of patients undergoing elective percutaneous coronary intervention at a tertiary cardiovascular centre in Trinidad: the POINT pilot study. 61
30997117 2019
The Effect of CYP2C19 and Nongenetic Factors on Clopidogrel Responsiveness in the MENA Region: A Systematic Review. 61
31512486 2019
Association of CYP2C19*2 polymorphism with clopidogrel resistance among patients with high cardiovascular risk in Northeastern Mexico. 61
31834317 2019
[Genetic and non-genetic factors of laboratory resistance to clopidogrel in patients with ischemic stroke]. 61
31184624 2019
Comparison of Clopidogrel and Ticlopidine/Ginkgo Biloba in Patients With Clopidogrel Resistance and Carotid Stenting. 61
30761076 2019
[Differential expression of lncRNA in patients with coronary artery disease plus clopidogrel resistance]. 61
30837396 2019
A Review of Danshen Combined with Clopidogrel in the Treatment of Coronary Heart Disease. 61
30911318 2019
Investigating the Effect of Demographics, Clinical Characteristics, and Polymorphism of MDR-1, CYP1A2, CYP3A4, and CYP3A5 on Clopidogrel Resistance. 61
30422888 2018
Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy. 61
29520080 2018
Laboratory assessments of therapeutic platelet inhibition in endovascular neurosurgery: comparing results of the VerifyNow P2Y12 assay to thromboelastography with platelet mapping. 61
29271717 2018
Effects of different CYP2C19 genotypes on prognosis of patients complicated with atrial fibrillation taking clopidogrel after PCI. 61
30233700 2018
Low-Dose Prasugrel in Patients with Resistance to Clopidogrel for the Treatment of Cerebral Aneurysms. 61
30196683 2018
Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles. 61
29804161 2018
Variable gender-dependent platelet responses to combined antiplatelet therapy in patients with stable coronary-artery disease. 61
30552303 2018
Is Preoperative Clopidogrel Resistance a Predictor of Bleeding and Risks in Patients Undergoing Emergency CABG Surgery? 61
30184029 2018
Association between CYP2C19 genotype and the additional effect of cilostazol to clopidogrel resistance in neuroendovascular therapy. 61
29915438 2018
Haemostaseological complication management in caval and iliac venous stenting. 61
29336234 2018
Response to clopidogrel is associated with early neurological deterioration after acute ischemic stroke. 61
29731992 2018
Impact of adenosine A2a receptor polymorphism rs5751876 on platelet reactivity in ticagrelor treated patients. 61
29355684 2018
Comment on "Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients". 61
29424732 2018
Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients. 61
29350207 2018
Two-year clinical outcomes after implantation of an everolimus-eluting bioresorbable scaffold (Absorb) in stable angina and acute coronary syndrome patients. Single-centre real-life registry data. 61
30008766 2018
Association of N6AMT1 rs2254638 Polymorphism With Clopidogrel Response in Chinese Patients With Coronary Artery Disease. 61
30283338 2018
The Impact of Clopidogrel Resistance on Clinical Outcome of Iranian Patients Undergoing Percutaneous Coronary Intervention. 61
30127832 2018

Variations for Clopidogrel Resistance

Expression for Clopidogrel Resistance

Search GEO for disease gene expression data for Clopidogrel Resistance.

Pathways for Clopidogrel Resistance

Pathways related to Clopidogrel Resistance according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
6 12.03 VASP P2RY12 P2RY1 ITGB3
Show member pathways
12.01 CYP3A5 CYP3A4 CYP2C9 CYP2C19 ABCB1
8 11.99 PTGS2 CYP2J2 CYP2C9 CYP2C19
Show member pathways
Show member pathways
11.92 CYP3A5 CYP3A4 CYP2C9 CYP2C19 CYP1A2 CYP1A1
Show member pathways
11.88 CYP3A4 CYP2J2 CYP1A2 CYP1A1
12 11.8 PTGS2 KDR ITGB3
Show member pathways
11.75 CYP3A4 CYP1A2 CYP1A1
Show member pathways
15 11.7 HMGCR CYP3A4 ABCB1
Show member pathways
11.7 CYP3A5 CYP3A4 CYP1A2 CYP1A1
Show member pathways
11.63 PON1 P2RY12 CYP3A5 CYP3A4 CYP2C9 CYP2C19
Show member pathways
Show member pathways
11.61 CYP3A5 CYP3A4 ABCB1
Show member pathways
11.61 CYP3A5 CYP3A4 CYP2C9 CYP2C19 CYP1A2 CYP1A1
21 11.52 PTGS2 CYP2J2 CYP1A1
22 11.51 PTGS2 CYP1A2 CYP1A1
23 11.4 CYP3A5 CYP3A4 ABCB1
24 11.39 CYP2C19 CYP1A2 CYP1A1
25 11.39 CYP3A4 CYP2C9 CYP1A2 ABCB1
Show member pathways
11.39 CYP3A5 CYP3A4 CYP2C9 CYP2C19 CYP1A2 CYP1A1
27 11.38 CYP3A5 CYP3A4 CYP2C9 CYP2C19 ABCB1
Show member pathways
11.35 CYP3A4 CYP1A2 CYP1A1
Show member pathways
30 11.27 P2RY12 P2RY1 ITGB3 CYP3A5 CYP3A4 CYP2C9
Show member pathways
11.23 PTGS2 CYP2J2 CYP2C9
32 11.22 CYP3A4 CYP2C9 CYP1A2 CYP1A1
33 11.15 CYP3A5 CYP3A4 CYP1A2
34 11.08 CYP3A4 CYP2C9 ABCB1
Show member pathways
10.98 CYP3A4 CYP1A2 CYP1A1
37 10.94 CYP3A5 CYP3A4 ABCB1
38 10.92 CYP3A4 ABCB1
39 10.79 CYP1A2 CYP1A1
Show member pathways
41 10.75 CYP3A5 CYP3A4 ABCB1
42 10.51 CYP2J2 CYP2C9

GO Terms for Clopidogrel Resistance

Cellular components related to Clopidogrel Resistance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.22 VASP SELP PTGS2 P2RY12 P2RY1 KDR
2 endoplasmic reticulum GO:0005783 9.96 PTGS2 KDR HMGCR CYP3A5 CYP3A4 CYP2J2
3 endoplasmic reticulum membrane GO:0005789 9.81 PTGS2 HMGCR CYP3A5 CYP3A4 CYP2J2 CYP2C9
4 intracellular membrane-bounded organelle GO:0043231 9.65 PTGS2 PON1 HMGCR CYP3A5 CYP3A4 CYP2J2
5 filopodium membrane GO:0031527 9.4 VASP ITGB3
6 platelet alpha granule membrane GO:0031092 9.37 SELP ITGB3
7 organelle membrane GO:0031090 9.23 PTGS2 CYP3A5 CYP3A4 CYP2J2 CYP2C9 CYP2C19

Biological processes related to Clopidogrel Resistance according to GeneCards Suite gene sharing:

(show all 45)
# Name GO ID Score Top Affiliating Genes
1 oxidation-reduction process GO:0055114 10.19 PTGS2 HMGCR CYP3A5 CYP3A4 CYP2J2 CYP2C9
2 fatty acid metabolic process GO:0006631 10.02 PTGS2 CYP3A4 CYP2J2 CYP2C19 CYP1A2 CYP1A1
3 response to drug GO:0042493 9.99 PTGS2 CYP1A2 CYP1A1 ABCB1
4 xenobiotic metabolic process GO:0006805 9.97 CYP3A5 CYP3A4 CYP2J2 CYP2C9 CYP2C19 CYP1A2
5 cholesterol metabolic process GO:0008203 9.96 PON1 HMGCR CYP3A4 CYP2C9 CYP1A2
6 aging GO:0007568 9.94 PTGS2 P2RY1 HMGCR CYP1A1
7 response to lipopolysaccharide GO:0032496 9.93 SELP PTGS2 CYP1A2 CYP1A1
8 retinol metabolic process GO:0042572 9.88 CYP3A5 CYP3A4 CYP1A2 CYP1A1
9 response to organic cyclic compound GO:0014070 9.87 PTGS2 CYP1A2 CYP1A1
10 platelet activation GO:0030168 9.87 P2RY12 P2RY1 ITGB3
11 response to organic substance GO:0010033 9.85 PTGS2 CYP1A2 CYP1A1
12 cellular response to organic cyclic compound GO:0071407 9.83 P2RY12 P2RY1 CYP1A1
13 oxidative demethylation GO:0070989 9.83 CYP3A5 CYP3A4 CYP2C9 CYP1A2
14 steroid biosynthetic process GO:0006694 9.82 HMGCR CYP3A4 CYP1A1
15 omega-hydroxylase P450 pathway GO:0097267 9.81 CYP2C9 CYP2C19 CYP1A2 CYP1A1
16 exogenous drug catabolic process GO:0042738 9.8 CYP3A4 CYP2J2 CYP2C9 CYP2C19 CYP1A2
17 heterocycle metabolic process GO:0046483 9.78 CYP3A4 CYP2C19 CYP1A2 CYP1A1
18 arachidonic acid metabolic process GO:0019369 9.77 CYP2J2 CYP2C9 CYP1A2
19 organic acid metabolic process GO:0006082 9.77 CYP2J2 CYP2C9 CYP2C19
20 drug metabolic process GO:0017144 9.77 CYP3A4 CYP2C9 CYP2C19 CYP1A2 CYP1A1
21 cellular response to ATP GO:0071318 9.76 PTGS2 P2RY12 P2RY1
22 drug catabolic process GO:0042737 9.76 CYP3A5 CYP3A4 CYP2C9 CYP1A2
23 lipid hydroxylation GO:0002933 9.74 CYP3A5 CYP3A4 CYP1A1
24 monoterpenoid metabolic process GO:0016098 9.73 CYP3A4 CYP2C9 CYP2C19 CYP1A2
25 long-chain fatty acid biosynthetic process GO:0042759 9.72 PTGS2 CYP3A4 CYP2C9 CYP1A2 CYP1A1
26 response to fatty acid GO:0070542 9.7 PTGS2 PON1
27 lipoxygenase pathway GO:0019372 9.69 PTGS2 PON1
28 vitamin D metabolic process GO:0042359 9.68 CYP3A4 CYP1A1
29 G protein-coupled purinergic nucleotide receptor signaling pathway GO:0035589 9.68 P2RY12 P2RY1
30 negative regulation of blood vessel diameter GO:0097756 9.67 PTGS2 HMGCR
31 glial cell migration GO:0008347 9.67 P2RY12 P2RY1
32 toxin metabolic process GO:0009404 9.67 CYP1A2 CYP1A1
33 adenosine receptor signaling pathway GO:0001973 9.66 P2RY12 P2RY1
34 hydrogen peroxide biosynthetic process GO:0050665 9.66 CYP1A2 CYP1A1
35 negative regulation of norepinephrine secretion GO:0010700 9.65 P2RY12 P2RY1
36 epoxygenase P450 pathway GO:0019373 9.65 CYP2J2 CYP2C9 CYP2C19 CYP1A2 CYP1A1
37 positive regulation of ion transport GO:0043270 9.64 P2RY12 P2RY1
38 porphyrin-containing compound metabolic process GO:0006778 9.63 CYP1A2 CYP1A1
39 steroid catabolic process GO:0006706 9.62 CYP3A4 CYP1A2
40 monocarboxylic acid metabolic process GO:0032787 9.62 CYP2C9 CYP1A2
41 dibenzo-p-dioxin metabolic process GO:0018894 9.61 CYP1A2 CYP1A1
42 alkaloid catabolic process GO:0009822 9.61 CYP3A5 CYP3A4
43 estrogen metabolic process GO:0008210 9.55 CYP3A5 CYP3A4 CYP2C9 CYP1A2 CYP1A1
44 steroid metabolic process GO:0008202 9.5 HMGCR CYP3A5 CYP3A4 CYP2C9 CYP2C19 CYP1A2
45 lipid metabolic process GO:0006629 9.32 PTGS2 PON1 HMGCR CYP3A5 CYP3A4 CYP2J2

Molecular functions related to Clopidogrel Resistance according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 metal ion binding GO:0046872 10.29 SELP PTGS2 PON1 CYP3A5 CYP3A4 CYP2J2
2 oxidoreductase activity GO:0016491 10.11 PTGS2 HMGCR CYP3A5 CYP3A4 CYP2J2 CYP2C9
3 enzyme binding GO:0019899 10 PTGS2 ITGB3 CYP3A4 CYP2C19 CYP1A2 CYP1A1
4 iron ion binding GO:0005506 9.95 CYP3A5 CYP3A4 CYP2J2 CYP2C9 CYP2C19 CYP1A2
5 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.87 CYP3A5 CYP3A4 CYP2J2 CYP2C9 CYP2C19 CYP1A2
6 monooxygenase activity GO:0004497 9.85 CYP3A5 CYP3A4 CYP2C9 CYP2C19 CYP1A2 CYP1A1
7 oxygen binding GO:0019825 9.81 CYP3A5 CYP3A4 CYP2C19 CYP1A1
8 heme binding GO:0020037 9.76 PTGS2 CYP3A5 CYP3A4 CYP2J2 CYP2C9 CYP2C19
9 estrogen 16-alpha-hydroxylase activity GO:0101020 9.73 CYP3A5 CYP3A4 CYP1A2 CYP1A1
10 steroid hydroxylase activity GO:0008395 9.73 CYP3A5 CYP3A4 CYP2J2 CYP2C9 CYP2C19 CYP1A1
11 arachidonic acid epoxygenase activity GO:0008392 9.71 CYP2J2 CYP2C9 CYP2C19
12 estrogen 2-hydroxylase activity GO:0101021 9.67 CYP3A4 CYP1A2 CYP1A1
13 caffeine oxidase activity GO:0034875 9.65 CYP3A4 CYP2C9 CYP1A2
14 G protein-coupled purinergic nucleotide receptor activity GO:0045028 9.58 P2RY12 P2RY1
15 retinoic acid 4-hydroxylase activity GO:0008401 9.58 CYP3A5 CYP3A4
16 demethylase activity GO:0032451 9.57 CYP1A2 CYP1A1
17 testosterone 6-beta-hydroxylase activity GO:0050649 9.56 CYP3A5 CYP3A4
18 vitamin D 24-hydroxylase activity GO:0070576 9.55 CYP3A4 CYP1A1
19 aromatase activity GO:0070330 9.43 CYP3A5 CYP3A4 CYP2C9 CYP2C19 CYP1A2 CYP1A1
20 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen GO:0016712 9.17 CYP3A5 CYP3A4 CYP2J2 CYP2C9 CYP2C19 CYP1A2

Sources for Clopidogrel Resistance

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....